China's Jiyuan Bio raises ~$15M Series B for cell immunotherapy
What's the deal? Hangzhou Jiyuan Gene Technology has raised nearly US$13.8M in a Series B round to advance its cell-based cancer immunotherapy work. The round was co-led by Wuxi Xichuang Xingwu Equity Investment Fund — managed by Wuxi Innovation Investment GroupDealroom has a profile for this one. Try Dealroom → — and the Vivo (Suzhou) Health Industry Investment Fund.
What does it do? Jiyuan develops cell immunotherapy products aimed at treating malignant tumours, using what it describes as leading gene technology. It is building teams, converting patented technology, developing new product processes, and running pilot-scale production.
What's the endgame? The company is pursuing an iPSC-derived immune-cell approach, with its lead candidate CG101 having cleared a US Food and Drug Administration investigational new drug application. The funding is earmarked for international trials and an expanded R&D and GMP base in Wuxi.
Why now? China's cell-and-gene-therapy sector is in a funding rebound. One industry tally put first-half 2026 financing at more than US$343.8M, with a separate tracker reporting $836 million in cell and gene therapy funding — near the full-year 2025 total.
What could go wrong? Jiyuan's round is modest next to peers; Shanghai-based Simnova raised nearly $60 million in August. Its significance rests on whether CG101 can move from IND clearance into clinical evidence, making trial progress and manufacturing capability the milestones to watch.
The signal: Investors are warming to off-the-shelf cell therapies, and Jiyuan's bet on iPSC-derived immune cells sits at the emerging edge of that trend. In a recovering market, execution — not the raise — will decide whether the approach pays off.
Read more: itjuzi.com
Image credit: Generated with Gemini